<code id='3D7FF894FC'></code><style id='3D7FF894FC'></style>
    • <acronym id='3D7FF894FC'></acronym>
      <center id='3D7FF894FC'><center id='3D7FF894FC'><tfoot id='3D7FF894FC'></tfoot></center><abbr id='3D7FF894FC'><dir id='3D7FF894FC'><tfoot id='3D7FF894FC'></tfoot><noframes id='3D7FF894FC'>

    • <optgroup id='3D7FF894FC'><strike id='3D7FF894FC'><sup id='3D7FF894FC'></sup></strike><code id='3D7FF894FC'></code></optgroup>
        1. <b id='3D7FF894FC'><label id='3D7FF894FC'><select id='3D7FF894FC'><dt id='3D7FF894FC'><span id='3D7FF894FC'></span></dt></select></label></b><u id='3D7FF894FC'></u>
          <i id='3D7FF894FC'><strike id='3D7FF894FC'><tt id='3D7FF894FC'><pre id='3D7FF894FC'></pre></tt></strike></i>

          fashion

          fashion

          author:Wikipedia    Page View:217
          2020 Biogen
          Steven Senn/AP

          Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy, is now a cautionary tale in pharmaceutical history.

          This week Biogen said it would no longer sell or study the medicine, which first won approval in 2021, ending an era for one of biotech’s storied companies and leaving the rest of the industry to piece together the lessons of a would-be blockbuster that never took off.

          advertisement

          STAT reporters took a stab at the Aduhelm legacy — for biotech, Biogen, and Alzheimer’s research — on a recent episode of the Readout LOUD. Here’s an edited transcript of that conversation.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          Medicare says breakthrough device reimbursement rule to come by summer
          Medicare says breakthrough device reimbursement rule to come by summer

          AfederalrulethatcouldmakeMedicarereimbursementforbreakthroughdeviceseasierisslatedforearlysummer.Ado

          read more
          Apple is now the first public company to be valued at $3 trillion
          Apple is now the first public company to be valued at $3 trillion

          6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

          read more

          Readout LOUD podcast: What to know about H5N1 bird flu

          Whathappenswhenacommonvirusjumpsfrombirdstocows?Andshouldwebeconcerned?Thisweekon“TheReadoutLOUD,”ST